Pacira Biosciences, Inc. - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.) on October 31, 2011. The filing primarily serves to announce the company's financial results for the fiscal quarter ended September 30, 2011, and to report a significant regulatory milestone.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes and Events
- Regulatory Approval: On October 31, 2011, the U.S. Food and Drug Administration (FDA) approved EXPAREL (bupivacaine liposome injectable suspension) 1.3%. This product is indicated for administration into the surgical site to produce postsurgical analgesia.
- Financial Results: The company announced its results for the fiscal quarter ended September 30, 2011, via a press release (Exhibit 99.1).
Guidance, Outlook, and Risks
The provided text does not contain specific management commentary, forward-looking guidance, risk factors, or contingencies. The filing explicitly states that the information in Item 2.02 and the attached exhibits shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings Press Release) for specific Q3 2011 financial figures including revenue, net loss, and cash position.
- Verify the commercial launch timeline and initial market reception for the newly FDA-approved EXPAREL product.
- Confirm the company's cash runway and capital requirements following the Q3 results.
- Check for any subsequent filings regarding the commercialization strategy for EXPAREL.